series-c-plus
Stage
3
Investors
About
NGM Biopharmaceuticals develops antibody-based therapeutics targeting the GDF15 pathway to treat conditions such as hyperemesis gravidarum and cancer cachexia.
Explore NGM Biopharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.